Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Okan Cetin, Patric Teodorescu, Andrew Staron, Vaishali Sanchorawala, Raphael E. Szalat

Blood (2024) 144 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2024-203221

Published: 2024

Journal Articles

Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis

Katie Y Li, Andrew Staron, Vaishali Sanchorawala, Raphael E. Szalat

Blood (2024) 144 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2024-200911

Published: 2024

Journal Articles

Abnormal Global Longitudinal Strain Correlates with Amyloidogenic Light Chain-Induced Cardiac Dysfunction via Direct Myocardial Toxicity in Patients without Significant Amyloid Fibril Deposition

Grace M. Ferri, Josue Villegas Galaviz, Tinuola Ajayi, Richard Giadone, George J. Murphy, Andrew Staron, Frederick L. Ruberg, Vaishali Sanchorawala, Camille V. Edwards

Blood (2023) 142 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2023-182520

Published: 2023

Journal Articles

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Andrew Staron, Eric J Burks, Raphael E Szalat, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2023-190813

Published: 2023

Journal Articles

Factors Underlying Impaired Organ Recovery Despite a Deep Hematologic Response in Patients with Systemic AL Amyloidosis

Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 3410.

https://doi.org/10.1182/blood-2023-189956

Published: 2023

Journal Articles

When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

Maya Abdallah, Frances Arters, Jasmine Patel, Matthew Lefebvre, Camille V. Edwards, Adam Lerner, Fabio Petrocca, Vaishali Sanchorawala, Andrew Staron, John Mark Sloan, Raphael E Szalat

Blood (2023) 142 (Supplement 1): 7432.

https://doi.org/10.1182/blood-2023-187811

Published: 2023

Journal Articles

Systemic AL Amyloidosis in Patients Younger Than 40 Years of Age: Clinical Presentation and Outcomes

Karina Verma, Andrew Staron, Luke Zheng, Gheorghe Doros, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 6762.

https://doi.org/10.1182/blood-2023-179597

Published: 2023

Journal Articles

Longitudinal Assessment and Prognostic Importance of Minimal Residual Disease (MRD) By Multiparametric Flow Cytometry in Patients with Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Eric Burks, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2021-149615

Published: 2021

Journal Articles

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Luke Zheng, Gheorghe Doros, Lawreen H Connors, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 155.

https://doi.org/10.1182/blood-2021-151804

Published: 2021

Journal Articles

Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes

Andrew Staron, Lawreen H Connors, PhD, Luke Zheng, BS, Gheorghe Doros, PhD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 51.

https://doi.org/10.1182/blood-2020-139751

Published: 2020

Journal Articles

The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades

Andrew Staron, Lawreen H Connors, Frederick L Ruberg, John L. Berk, Lisa M Mendelson, Vaishali Sanchorawala, MD

Blood (2018) 132 (Supplement 1): 5536.

https://doi.org/10.1182/blood-2018-99-112193

Published: 2018

NARROW

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis

Abnormal Global Longitudinal Strain Correlates with Amyloidogenic Light Chain-Induced Cardiac Dysfunction via Direct Myocardial Toxicity in Patients without Significant Amyloid Fibril Deposition

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Factors Underlying Impaired Organ Recovery Despite a Deep Hematologic Response in Patients with Systemic AL Amyloidosis

When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

Systemic AL Amyloidosis in Patients Younger Than 40 Years of Age: Clinical Presentation and Outcomes

Longitudinal Assessment and Prognostic Importance of Minimal Residual Disease (MRD) By Multiparametric Flow Cytometry in Patients with Systemic Light Chain (AL) Amyloidosis

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes

The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only